Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Feb;16(2):203-5.
doi: 10.5588/ijtld.11.0445.

Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis

S E Smith  1 , E V Kurbatova, J S Cavanaugh, J P Cegielski
Affiliations
Comparative Study

Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis

S E Smith et al. Int J Tuberc Lung Dis. 2012 Feb.

Abstract

Following the World Health Organization's endorsement of the Xpert® MTB/RIF assay, which rapidly and simultaneously diagnoses tuberculosis (TB) and detects resistance to rifampin (RMP), the question arises to what extent RMP resistance is an adequate marker for multidrug-resistant TB (MDR-TB). A retrospective analysis of data from >81 countries and subnational settings demonstrated that >40% of RMP-resistant isolates from new TB cases did not display resistance to isoniazid (INH) in settings with relatively low MDR-TB prevalence (one third of all countries and subnational settings). Results indicated the need for INH susceptibility testing in addition to RMP susceptibility testing.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest. All authors declare no conflict of interest.

References

    1. World Health Organization. Rapid Implementation of the Xpert MTB/RIF diagnostic test. Geneva, Switzerland: 2011.
    1. Boehme CC, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005–15. - PMC - PubMed
    1. Boehme CC, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495–505. - PMC - PubMed
    1. Aziz MA, et al. WHO, editor. Anti-tuberculosis drug resistance in the world: third global report. WHO; Geneva: 2004.
    1. Espinal MA, et al. Anti-tuberculosis drug resistance in the world: report no. 2. WHO; 2000.

MeSH terms

LinkOut - more resources